Connect with us

News

FDA fast-tracks ovarian cancer drug

Published

on

The US Food and Drug Administration (FDA) has granted fast track status to stenoparib, an ovarian cancer drug for patients who cannot tolerate platinum-based treatments.

The designation, given to medicines addressing serious medical needs, allows more frequent FDA communication and may enable accelerated approval if criteria are met.

Allarity Therapeutics is developing stenoparib as an option for women with advanced ovarian cancer who have hypersensitivity to platinum drugs such as cisplatin and carboplatin, or whose tumours no longer respond to these therapies.

Ovarian cancer begins in the reproductive organs that produce eggs.

While platinum drugs can shrink tumours and slow their growth, some patients cannot take them due to health complications or allergic reactions to the metal.

Thomas Jensen, chief executive officer of Allarit, said: “We are very pleased that the FDA has granted fast track designation to stenoparib.

“We look forward to engaging closely with the FDA as we advance this program.”

Jensen added that the designation “underscores the significant unmet need facing women with advanced ovarian cancer and reflects the potential of stenoparib to meaningfully improve treatment outcomes.”

Stenoparib, first developed by Eisai as E7449 and later called 2X-121, is an oral small molecule that blocks PARP1/2 and tankyrase 1/2 enzymes – proteins involved in cancer cell growth.

Blocking these enzymes is expected to slow tumour progression.

A Phase 1 clinical trial (NCT01618136) showed stenoparib as an add-on treatment was well tolerated and prolonged survival in patients with solid cancers, including five with ovarian cancer.

Phase 1 trials test safety and dosing in small groups.

Allarity is now enrolling patients in a Phase 2 study to determine the best dose – 600mg or 800mg daily as hard gelatin capsules – for women with advanced, recurrent ovarian cancer who cannot take platinum drugs or whose tumours are resistant.

Phase 2 trials test effectiveness in larger patient groups.

Several patients have been receiving treatment since June. The study will measure clinical benefit, progression-free and overall survival, disease control, and response rates over about two years.

The company is using its Drug Response Predictor (DRP) platform to identify patients whose tumour genetics suggest they are likely to respond to stenoparib.

DRP also helps identify biomarkers of response or resistance to treatment.

Fast track designation may also give access to accelerated approval, priority review, or rolling review, potentially bringing the drug to patients more quickly than standard processes.

Menopause

Resistance training has preventative effects in menopause, study finds

Published

on

Resistance training improves hip strength, balance and flexibility during menopause and may also improve lean body mass, research suggests.

A study of 72 active women aged 46 to 57 found those who completed a 12-week supervised programme saw greater gains than those who kept to their usual exercise routines.

None of the participants were taking hormone replacement therapy.

The supervised, low-impact resistance exercise programme focused on strength at the hip and shoulder, dynamic balance and flexibility.

Participants used Pvolve equipment, including resistance bands and weights around the hips, wrists and ankles, and also lifted dumbbells of varying loads.

Women in the resistance training group showed a 19 per cent increase in hip function and lower-body strength, a 21 per cent increase in full-body flexibility and a 10 per cent increase in dynamic balance, meaning the ability to stay stable while moving.

Those in the usual activity group did not show any significant improvements.

Previous studies have assessed the decline in lower limb strength and flexibility during menopause, but this is said to be the first study to compare the effect of resistance training on muscle strength and mass before, during and after menopause.

This was done by including participants in different phases of menopause rather than following the same participants over a long timeframe.

Francis Stephens, a researcher at the University of Exeter Medical School in the UK, said: “These results are important because women appear to be more susceptible to loss of leg strength as they age, particularly after menopause, which can lead to increased risk of falls and hip fractures.

“This is the first study to demonstrate that a low-impact bodyweight and resistance band exercise training programme with a focus on the lower limbs, can increase hip strength, balance, and flexibility.

“Importantly, these improvements were the same in peri- and post-menopausal females when compared to pre-menopausal females, suggesting that changes associated with menopause do not mitigate the benefits of exercise.”

Although one of the researchers sits on Pvolve’s clinical advisory board, the researchers said the company did not sponsor the study or influence its results.

Stephens added that any progressive resistance exercise training focused on lower-body strength is likely to yield the same results.

He said: “The important point is for an individual to find a type of exercise, modality, location, time of day etc., that is enjoyable, sustainable, and improves everyday life.

“The participants in the present study reported an improvement in ‘enjoyment of exercise,’ and some are still using the programme since the study finished.”

Kylie Larson, a women’s health and fitness coach and founder of Elemental Coaching, who was not involved in the study, said the results were compelling.

She said: “This is particularly exciting for those that tend to think of menopause as ‘the end’. The study proves that if you incorporate strength training you can still make improvements to your muscle mass and strength, which will also have a positive ripple effect to your ability to manage your body composition.

“In addition, staying flexible and being able to balance are both keys to a healthy and functional second half of life.”

Participants in the study did four classes a week for 30 minutes each session, but Larson said even half that amount of strength training can go a long way, particularly if you emphasise progressive overload, which means gradually increasing muscle challenge through more weight.

Larson said: “Gradually increasing the challenge is what drives real change.

“Lifting heavier over time is what builds strength, protects your bones, and keeps your body resilient through menopause and beyond.”

Continue Reading

Adolescent health

France to reimburse young women for cost of reusable period products

Published

on

France will reimburse reusable period products for women under 26 and those on low incomes, in a move aimed at tackling period poverty.

The measure is expected to help 6.7m people, almost a tenth of France’s population of 69m, from the start of the next academic year in the autumn.

Women under 26 with a state health insurance card, as well as women of all ages who receive special healthcare support because of limited income, will be able to claim reimbursement after buying the products from a pharmacy. The cost will be covered through the country’s social security system.

Parliament approved the measure as part of the country’s social security budget for 2024. However, no decree was issued to bring it into force, prompting anger among feminist groups and companies making the sustainable sanitary items.

A survey of 4,000 women in France in November found that one in ten had used alternatives to mainstream period products, such as ripped-up clothes, because of tight budgets, according to French charity Dons Solidaires.

France cut sales tax on period products from 20 per cent to 5.5 per cent in 2016. In 2020, Scotland became the first country in the world to sign into law free universal access to period products in public buildings.

Continue Reading

News

Condé Nast to close women’s health magazine after 47 years

Published

on

Condé Nast will close its women’s health publication Self after 47 years, with unprofitable editions of Glamour and Wired also set to shut.

In a memo published on the magazine giant’s website on Thursday, the media company’s chief executive, Roger Lynch, said: “As audience behaviours shift, we have not seen a path for Self to continue in its current form as a digital publication.”

“Going forward, health and wellness content will be integrated into our other brands, including Allure and Glamour,” Lynch said, referring to Condé Nast’s other beauty and wellness titles.

Self, which moved to an online-only format in 2017, still reaches more than 20m people each month.

The publication has also earned significant recognition over the years, including a National Magazine award and a Webby’s People’s Voice award.

The closure is part of a wider set of operational changes across the company. Lynch also announced the end of Wired’s Italy edition, noting that while the brand “remains a strong global brand, the Italian edition has not kept pace with growth in our other markets”.

Condé Nast will also wind down Glamour’s publishing operations in Germany, Spain and Mexico.

Lynch said: “Taken together, Wired in Italy, Self and the affected Glamour markets represent a little over 1 per cent of our overall revenue.

“They also remain unprofitable, and continuing to operate them in their current form limits our ability to invest in the ideas and areas that will drive future growth.”

Beyond editorial changes, the company is also restructuring internally to adapt to technological shifts.

Lynch said Condé Nast would make “changes within our technology organisation, reflecting the rapid advancement of AI and its impact on our ability to innovate and build products faster”, adding: “Teams will be restructured to be more agile and to work more closely with our brands and customers, reducing barriers to execution.”

The latest moves follow a series of transformations at Condé Nast in recent years.

Glamour ended its print edition in 2018, followed by Allure moving to a digital-only format in 2022.

In 2024, music publication Pitchfork was folded into GQ, the company’s men’s style magazine.

More recently, last November, Vogue, one of Condé Nast’s key revenue drivers, announced it would absorb Teen Vogue to create a more “unified reader experience across titles”.

The media industry has been shrinking steadily over the years.

From 2010 to 2017, the industry lost an average of 7,305 jobs annually, according to data from Challenger, Gray & Christmas published in December 2025.

Since 2018, the average number of job cuts in the industry has risen to 14,298 a year.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.